Lymphoid Hematological Malignancies Clinical Trials in Zurich, Canton of Zurich

Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)